Extended Pouch Roux-en-Y Gastric Bypass Study
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02218957 |
|
Recruitment Status : Unknown
Verified June 2016 by Rijnstate Hospital.
Recruitment status was: Active, not recruiting
First Posted : August 18, 2014
Last Update Posted : June 3, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Morbid obesity is an increasing medical problem in the western countries. It's related to comorbidities as diabetes mellitus, hypertension, OSAS, arthrosis and hypercholesterolemia. The Roux-en-Y Gastric Bypass (RYGB) is an effective surgical therapy for morbidly obese patients. A part of these patients will have disappointing results, and have weight regain on the long term. Some studies show more weight reduction by increasing the biliopancreatic limb in patients with morbid obesity.
The objective of this study is to investigate the effect of a restrictive/extended pouch on weight reduction in morbidly obese patients undergoing RYGB-surgery. We hypothesize that the restrictive/extended pouch results in more weight reduction.
The study design is a prospective, randomized control trial. The patients will be randomized in 2 groups: a standard RYGB (normal pouch) and restrictive/extended pouch RYGB.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Morbid Obesity | Procedure: Extended Pouch RYGB Procedure: Standard RYGB | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 130 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Single (Participant) |
| Primary Purpose: | Treatment |
| Official Title: | Restrictive Extended Pouch in Roux-en-Y Gastric Bypass: a Prospective Randomized Control Trial |
| Study Start Date : | August 2014 |
| Estimated Primary Completion Date : | October 2017 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Standard RYGB
Standard RYGB
|
Procedure: Standard RYGB |
|
Experimental: Extended Pouch RYGB
Restrictive/extended pouch RYGB
|
Procedure: Extended Pouch RYGB |
- Weight reduction [ Time Frame: 2 years ]Excess weight loss (%EWL)
- Change in comorbidities [ Time Frame: 2 years ]
Preoperatively the number of patients with comorbidities will be calculated. At two year follow-up this will be calculated again. Patients will be divided in groups:
- comorbidity resolved
- comorbidity improved
- comorbidity unchanged
- comorbidity worsened
This will be done for diabetes mellitus, hypertension, dislipedimia and OSAS.
- Change in comorbidities [ Time Frame: 2 years ]
Preoperatively the number of patients with comorbidities will be calculated. At two year follow-up this will be calculated again. Patients will be divided in groups:
- comorbidity resolved
- comorbidity improved
- comorbidity unchanged
- comorbidity worsened
This will be done for diabetes mellitus, hypertension, dislipidemia and OSAS.
- Complications [ Time Frame: 2 years ]Complications will be divided in short-term complications (within 30 days after operation) and long-term complications (after 30 days). All adverse event will be registered.
- Quality of life [ Time Frame: 2 years ]The quality of life will be assessed by using the BAROS.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Patient eligible for bariatric surgery according Fried guidelines
Primary Gastric bypass
- BMI 35 - 40 with a comorbidity
- or BMI > 40
Exclusion Criteria:
- Exclusion criteria for bariatric surgery (Fried Guidelines)
- Patients with language problems that interveins to follow medical advises
- Genetic diseases that intervens to follow medical advises
- Chronic bowel diseases
- Nephrologic (MDRD <30) of liver diseases (AST/ALT more than twice the norm)
- Pregnancy
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02218957
| Netherlands | |
| Rijnstate Hospital | |
| Arnhem, Gelderland, Netherlands, 6800WC | |
| Principal Investigator: | Jens Homan, MD | Rijnstate Hospital Arnhem |
| Responsible Party: | Rijnstate Hospital |
| ClinicalTrials.gov Identifier: | NCT02218957 |
| Other Study ID Numbers: |
ExtPouch |
| First Posted: | August 18, 2014 Key Record Dates |
| Last Update Posted: | June 3, 2016 |
| Last Verified: | June 2016 |
|
Bariatric surgery Roux-en-Y Gastric Bypass |
|
Obesity, Morbid Obesity Overnutrition |
Nutrition Disorders Overweight Body Weight |

